Cytokinetics
CYTK
142 hedge funds and large institutions have $584M invested in Cytokinetics in 2019 Q4 according to their latest regulatory filings, with 25 funds opening new positions, 51 increasing their positions, 41 reducing their positions, and 25 closing their positions.
24% more repeat investments, than reductions
Existing positions increased: 51 | Existing positions reduced: 41
16.24% more ownership
Funds ownership: 76.89% → 93.13% (+16%)
14% more capital invested
Capital invested by funds: $513M → $584M (+$70.5M)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 25
4% less funds holding
Funds holding: 148 → 142 (-6)
13% less call options, than puts
Call options by funds: $2.59M | Put options by funds: $2.98M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$31.2M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$26.7M |
| 3 |
Morgan Stanley
New York
|
+$11.2M |
| 4 |
Jennison Associates
New York
|
+$6.27M |
| 5 |
Millennium Management
New York
|
+$5.94M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$8.57M |
| 2 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$7.4M |
| 3 |
SI
Sofinnova Investments
Menlo Park,
California
|
-$2.4M |
| 4 |
PVI
Pura Vida Investments
New York
|
-$2.14M |
| 5 |
N
Nuveen
Charlotte,
North Carolina
|
-$1.79M |
CYTK Hedge Fund Activity: Q4 2019 in Review
142 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Cytokinetics (CYTK) for Q4 2019, worth a combined $584M — up 14% from $513M a quarter earlier.
Fund positioning in CYTK was balanced in Q4 2019: 25 funds opened new positions, 25 closed out, 51 added to existing stakes and 41 trimmed.
The largest buyer was BVF Inc, adding an estimated $31.2M. The largest seller was Federated Hermes, cutting an estimated $8.57M.
- 142 institutional investors held Cytokinetics (CYTK) as of Q4 2019, down from 148 in Q3 2019.
- Funds reported $584M of Cytokinetics stock for Q4 2019, up 14% quarter-over-quarter.
- 25 funds opened new Cytokinetics positions in Q4 2019 and 25 closed out, a net change of 0 holders.
- The largest Cytokinetics buyer in Q4 2019 was BVF Inc, an estimated $31.2M added.
- The largest Cytokinetics seller in Q4 2019 was Federated Hermes, an estimated $8.57M sold.
Based on aggregated 13F filings for Q4 2019.